Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypersensitivity reactions to deoxycoformycin.

P J O'Dwyer1, S A King, E Eisenhauer

  • 1Investigational Drug Branch, National Cancer Institute Bethesda, MD.

Cancer Chemotherapy and Pharmacology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018
Same author

Barriers to participation in clinical trials: a physician survey.

Current oncology (Toronto, Ont.)·2018
Same author

Mental health services use by melanoma patients receiving adjuvant interferon: association of pre-treatment mental health care with early discontinuation.

Current oncology (Toronto, Ont.)·2017
Same author

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.

Gynecologic oncology·2009
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Deoxycoformycin (dCF) can cause allergic reactions beyond skin rash in patients with lymphoid cancers. Further research is needed to understand and manage these hypersensitivity reactions during treatment.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Deoxycoformycin (dCF) is an antineoplastic agent used for lymphoid malignancies like hairy cell leukemia (HCL).
  • Previous reports noted skin toxicity (maculopapular eruption) with dCF, but an allergic basis was unclear.
  • HCL and other lymphoid neoplasms are serious conditions requiring effective treatments.

Purpose of the Study:

  • To investigate the potential for Deoxycoformycin (dCF) to cause systemic hypersensitivity reactions.
  • To differentiate between idiosyncratic reactions and true allergic responses to dCF.
  • To highlight the need for further study into managing dCF-induced hypersensitivity.

Main Methods:

  • Case series presentation of five patients experiencing hypersensitivity reactions to dCF.

Related Experiment Videos

  • Clinical observation and documentation of systemic manifestations beyond skin eruption.
  • Analysis of reaction patterns to infer allergic etiology.

    • Main Results:

    • Five cases of Deoxycoformycin (dCF)-related hypersensitivity reactions were identified.
    • Systemic symptoms accompanying skin rash suggested an allergic basis for these reactions.
    • The findings indicate a potential for allergic responses to dCF in susceptible individuals.

    Conclusions:

    • Deoxycoformycin (dCF) can induce hypersensitivity reactions with systemic manifestations in patients with lymphoid neoplasms.
    • These reactions appear to have an allergic etiology, distinct from simple idiosyncratic toxicity.
    • Further investigation into the mechanisms and management of dCF hypersensitivity is warranted given its therapeutic value.